Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial

PURPOSE: Clinically validated biomarkers for anti-angiogenesis agents are not available. We have previously reported associations between candidate VEGFA SNPs and overall survival (OS) in E2100. The associations between tumor VEGFA amplification and outcome are evaluated here. PATIENTS AND METHODS:...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Schneider, Bryan P., Gray, Robert J., Radovich, Milan, Shen, Fei, Vance, Gail, Li, Lang, Jiang, Guanglong, Miller, Kathy D., Gralow, Julie R., Dickler, Maura N., Cobleigh, Melody A., Perez, Edith A., Shenkier, Tamara N., Nielsen, Kirsten Vang, Müller, Sven, Thor, Ann, Sledge, George W., Sparano, Joseph A., Davidson, Nancy E., Badve, Sunil S.
Format: Artigo
Idioma:Inglês
Publicat: 2013
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3594423/
https://ncbi.nlm.nih.gov/pubmed/23340303
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-3029
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars